Richard Schilsky to Precision Medicine
This is a "connection" page, showing publications Richard Schilsky has written about Precision Medicine.
Connection Strength
6.178
-
'Strategic' development of precision cancer medicine in the United States. Mol Oncol. 2021 07; 15(7):1747-1749.
Score: 0.587
-
Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies. J Oncol Pract. 2019 11; 15(11):575-583.
Score: 0.516
-
Implementing Precision Medicine in Community-Based Oncology Programs: Three Models. J Oncol Pract. 2019 06; 15(6):325-329.
Score: 0.500
-
The evidence framework for precision cancer medicine. Nat Rev Clin Oncol. 2018 03; 15(3):183-192.
Score: 0.460
-
Innovative clinical trials for development of personalized cancer medicine. Mol Oncol. 2015 May; 9(5):933-4.
Score: 0.379
-
Implementing personalized cancer care. Nat Rev Clin Oncol. 2014 07; 11(7):432-8.
Score: 0.356
-
Precision cancer medicine: the future is now, only better. Am Soc Clin Oncol Educ Book. 2014; 61-9.
Score: 0.350
-
Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. Am Soc Clin Oncol Educ Book. 2013; 118-25.
Score: 0.326
-
Personalized cancer medicine - a strategy to counteract an increasing cancer challenge. Mol Oncol. 2012 Apr; 6(2):109-10.
Score: 0.309
-
Using patient-initiated study participation in the development of evidence for personalized cancer therapy. Clin Cancer Res. 2011 Nov 01; 17(21):6651-7.
Score: 0.301
-
Clinical trials in the era of personalized oncology. CA Cancer J Clin. 2011 Nov-Dec; 61(6):365-81.
Score: 0.301
-
Tumor heterogeneity as the foundation of personalized cancer treatment. Semin Oncol. 2011 Apr; 38(2):171-2.
Score: 0.289
-
Personalized medicine in oncology: the future is now. Nat Rev Drug Discov. 2010 05; 9(5):363-6.
Score: 0.271
-
Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study. JCO Precis Oncol. 2024 Mar; 8:e2300615.
Score: 0.177
-
Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. J Clin Oncol. 2021 04 01; 39(10):1165-1184.
Score: 0.143
-
Accelerating anticancer drug development - opportunities and trade-offs. Nat Rev Clin Oncol. 2018 12; 15(12):777-786.
Score: 0.123
-
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015 Nov 10; 33(32):3817-25.
Score: 0.098
-
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget. 2015 Jun 10; 6(16):14139-52.
Score: 0.097
-
Integrating biomarkers in colorectal cancer trials in the West and China. Nat Rev Clin Oncol. 2015 Sep; 12(9):553-60.
Score: 0.096
-
Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol. 2015 Aug; 26(8):1791-8.
Score: 0.096
-
American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol. 2013 Dec 01; 31(34):4362-70.
Score: 0.086
-
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705.
Score: 0.070
-
Refocusing the war on cancer: the critical role of personalized treatment. Sci Transl Med. 2010 Apr 21; 2(28):28cm13.
Score: 0.068
-
The Porto European Cancer Research Summit 2021. Mol Oncol. 2021 10; 15(10):2507-2543.
Score: 0.037
-
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019 10; 574(7776):127-131.
Score: 0.033
-
Challenges and approaches to implementing master/basket trials in oncology. Blood Adv. 2019 07 23; 3(14):2237-2243.
Score: 0.032
-
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019 05; 25(5):751-758.
Score: 0.032
-
Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017 04 20; 35(12):1341-1367.
Score: 0.027
-
WIN Consortium--challenges and advances. Nat Rev Clin Oncol. 2011 Mar; 8(3):133-4.
Score: 0.018